STAT3 and colorectal carcinoma: Previous studies have shown that STAT3 was activated in TIICs, including TAMs, amplifying immune suppression, and targeting IL-6 to regulate STAT3 signaling pathway was considered a potential immunotherapy for CRC (Wang and Sun, 2014; Verdeil et al., 2019).